1023 related articles for article (PubMed ID: 27918780)
21. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo H; Sledge G; Koehler M; Ellis C; Casey M; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2010 Mar; 28(7):1124-30. PubMed ID: 20124187
[TBL] [Abstract][Full Text] [Related]
22. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Rugo HS; Pennella EJ; Gopalakrishnan U; Hernandez-Bronchud M; Herson J; Koch HF; Loganathan S; Deodhar S; Marwah A; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng MLT; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Roy S; Yanez Ruiz EP; Barve A; Fuentes-Alburo A; Waller CF
Breast Cancer Res Treat; 2021 Jul; 188(2):369-377. PubMed ID: 34125340
[TBL] [Abstract][Full Text] [Related]
23. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
24. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
25. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Vinnyk Y; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Moiseyenko V; Shparyk Y; Bello M; Semiglazov V; Song S; Lim J
J Clin Oncol; 2018 Apr; 36(10):968-974. PubMed ID: 29373094
[TBL] [Abstract][Full Text] [Related]
26. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.
Pivot X; Georgievich MA; Shamrai V; Dzagnidze G; Soo Hoo HF; Kaewkangsadan V; Petrelli F; Villanueva C; Nikolaevich LO; Hii J; Kim J; Pradhan S; Jaison L; Feyaerts P; Kaufman L; Derde MP; Bonamy GMC; Deforce F; Cox DG
JAMA Oncol; 2022 May; 8(5):698-705. PubMed ID: 35238873
[TBL] [Abstract][Full Text] [Related]
30. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
Xu B; Zhang Q; Sun T; Li W; Teng Y; Hu X; Bondarenko I; Adamchuk H; Zhang L; Trukhin D; Wang S; Zheng H; Tong Z; Shparyk Y; Wang Q;
BioDrugs; 2021 May; 35(3):337-350. PubMed ID: 33826080
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.
Nodehi RS; Kalantari B; Raafat J; Ansarinejad N; Moazed V; Mortazavizadeh SMR; Hosseinzadeh M; Ghaderi B; Jenabian A; Qadyani M; Haghighat S; Allahyari A; Mirzania M; Seghatoleslami M; Payandeh M; Alikhasi A; Kafi H; Shahi F
BMC Pharmacol Toxicol; 2022 Jul; 23(1):57. PubMed ID: 35902898
[TBL] [Abstract][Full Text] [Related]
34. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
36. Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.
Rugo HS; Pennella EJ; Gopalakrishnan U; Hernandez-Bronchud M; Herson J; Koch HF; Loganathan S; Deodhar S; Marwah A; Manikhas A; Bondarenko I; Parra JD; Abesamis-Tiambeng MLT; Akewanlop C; Vynnychenko I; Sriuranpong V; Roy S; Yanez Ruiz EP; Barve A; Waller CF
Breast; 2021 Aug; 58():18-26. PubMed ID: 33892316
[TBL] [Abstract][Full Text] [Related]
37. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.
Jackisch C; Stroyakovskiy D; Pivot X; Ahn JS; Melichar B; Chen SC; Meyenberg C; Al-Sakaff N; Heinzmann D; Hegg R
JAMA Oncol; 2019 May; 5(5):e190339. PubMed ID: 30998824
[TBL] [Abstract][Full Text] [Related]
40. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A; Wang T; Cortés J; Rexer B; Paré L; Forero A; Wolff AC; Morales S; Adamo B; Brasó-Maristany F; Vidal M; Veeraraghavan J; Krop I; Galván P; Pavlick AC; Bermejo B; Izquierdo M; Rodrik-Outmezguine V; Reis-Filho JS; Hilsenbeck SG; Oliveira M; Dieci MV; Griguolo G; Fasani R; Nuciforo P; Parker JS; Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF
J Natl Cancer Inst; 2020 Jan; 112(1):46-54. PubMed ID: 31037288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
